PMAM
VRTX icon

Picton Mahoney Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Picton Mahoney Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-12,684
Closed -$5.95M – 971
2024
Q2 		$5.95M Sell
12,684
-21
-0.2% -$9.12K 0.23% 143
2024
Q1 		$5.31M Sell
12,705
-1,482
-10% -$627K 0.16% 145
2023
Q4 		$5.77M Sell
14,187
-510
-3% -$188K 0.16% 127
2023
Q3 		$5.11M Buy
14,697
+707
+5% +$247K 0.15% 141
2023
Q2 		$4.92M Buy
13,990
+444
+3% +$150K 0.21% 141
2023
Q1 		$4.27M Sell
13,546
-20
-0.1% -$6K 0.19% 160
2022
Q4 		$3.92M Buy
13,566
+326
+2% +$99.4K 0.18% 157
2022
Q3 		$3.83M Buy
13,240
+3,505
+36% +$1.01M 0.14% 153
2022
Q2 		$2.75M Buy
+9,735
New +$2.61M 0.1% 298
2021
Q3 		– Sell
-8,620
Closed -$1.74M – 955
2021
Q2 		$1.74M Buy
+8,620
New +$1.8M 0.05% 414
2021
Q1 		– Sell
-34,670
Closed -$8.19M – 397
2020
Q4 		$8.19M Sell
34,670
-26,944
-44% -$6.18M 0.39% 79
2020
Q3 		$16.8M Sell
61,614
-27,090
-31% -$7.47M 0.93% 20
2020
Q2 		$25.8M Sell
88,704
-28,802
-25% -$7.81M 1.48% 10
2020
Q1 		$28M Sell
117,506
-14,447
-11% -$3.31M 1.58% 8
2019
Q4 		$28.9M Sell
131,953
-1,047
-0.8% -$212K 1.95% 9
2019
Q3 		$22.5M Sell
133,000
-15,639
-11% -$2.77M 1.59% 18
2019
Q2 		$27.3M Buy
148,639
+44,355
+43% +$7.75M 1.87% 10
2019
Q1 		$19.2M Buy
104,284
+820
+0.8% +$151K 1.45% 21
2018
Q4 		$17.1M Buy
103,464
+3,023
+3% +$524K 1.53% 17
2018
Q3 		$19.4M Sell
100,441
-759
-0.8% -$135K 1.36% 23
2018
Q2 		$17.2M Buy
101,200
+4,100
+4% +$636K 1.24% 23
2018
Q1 		$15.8M Buy
97,100
+3,200
+3% +$523K 1.14% 28
2017
Q4 		$14.1M Buy
93,900
+7,900
+9% +$1.17M 1.01% 38
2017
Q3 		$13.1M Buy
+86,000
New +$12.9M 0.98% 42

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Picton Mahoney Asset Management's VRTX Position: Q3 2024 in Review

Picton Mahoney Asset Management sold out of Vertex Pharmaceuticals (VRTX) in Q3 2024, closing a stake of 12,684 shares — an estimated $5.95M sold.

Picton Mahoney Asset Management first reported a position in VRTX in Q3 2017 and held it in 24 quarters. The position peaked at $28.9M in Q4 2019. 1,545 funds tracked by Wall St. Rank hold VRTX as of Q3 2024.

  • Picton Mahoney Asset Management reported no remaining Vertex Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Picton Mahoney Asset Management sold 12,684 Vertex Pharmaceuticals shares in Q3 2024, an estimated $5.95M.
  • Picton Mahoney Asset Management first reported a position in Vertex Pharmaceuticals in Q3 2017 and held it in 24 quarters.
  • Picton Mahoney Asset Management's Vertex Pharmaceuticals position peaked at $28.9M in Q4 2019.
  • 1,545 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2024.

Based on Picton Mahoney Asset Management's 13F filing for Q3 2024, filed 4 Nov 2024.